Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

[1]  M Nakajima,et al.  [Matrix metalloproteinase inhibitors]. , 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  N. Mitsiades,et al.  Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. , 1998, The Journal of clinical endocrinology and metabolism.

[3]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[4]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[5]  R. Chaby,et al.  Involvement of the membrane form of tumour necrosis factor‐&agr; in lipopolysaccharide‐induced priming of mouse peritoneal macrophages for enhanced nitric oxide response to lipopolysaccharide , 1997, Immunology.

[6]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[7]  P. J. Middelhoven,et al.  Involvement of a metalloprotease in the shedding of human neutrophil FcγRIIIB , 1997 .

[8]  P. M. Davis,et al.  Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. , 1997, Journal of immunology.

[9]  Mirna Tenan,et al.  Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors , 1997, Brain pathology.

[10]  P. McCann,et al.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. , 1997, Pharmacology & therapeutics.

[11]  R. Greil,et al.  Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. , 1997, Blood.

[12]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Loughran,et al.  Constitutive expression of Fas ligand in large granular lymphocyte leukaemia , 1997, British journal of haematology.

[14]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[15]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[16]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[17]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[18]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[19]  M. Martínez-Lorenzo,et al.  Release of preformed Fas ligand in soluble form is the major factor for activation‐induced death of Jurkat T cells , 1996, Immunology.

[20]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[21]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[22]  S. Nagata,et al.  An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand , 1996, British journal of haematology.

[23]  C. Lockwood,et al.  Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. , 1996, The Journal of clinical endocrinology and metabolism.

[24]  W. Stetler-Stevenson.  Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. , 1996, The American journal of pathology.

[25]  L. French,et al.  Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover , 1996, The Journal of cell biology.

[26]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[27]  H. Frierson,et al.  Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing sarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Kawasaki,et al.  Metalloproteinase-mediated release of human Fas ligand , 1995, The Journal of experimental medicine.

[29]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[30]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[31]  M. Weller,et al.  Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.

[32]  P. Krammer,et al.  Regulation of cell surface APO‐1/Fas (CD95) ligand expression by metalloproteases , 1995, European journal of immunology.

[33]  Wood,et al.  Matrix metalloproteinases and processing of pro‐TNF‐α , 1995, Journal of leukocyte biology.

[34]  Masato Tanaka,et al.  Expression of the functional soluble form of human fas ligand in activated lymphocytes. , 1995, The EMBO journal.

[35]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[36]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[37]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[38]  R. Bast,et al.  Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.

[39]  A. H. Drummond,et al.  Processing of tumour necrosis factor-α precursor by metalloproteinases , 1994, Nature.

[40]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[41]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[42]  P. Sorensen,et al.  Reverse Transcriptase PCR Amplification of EWS/FLI‐1 Fusion Transcripts as a Diagnostic Test for Peripheral Primitive Neuroectodermal Tumors of Childhood , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[43]  M. Pawlita,et al.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. , 1992, The Journal of biological chemistry.

[44]  I. Fidler.  Origin and biology of cancer metastasis. , 1989, Cytometry.

[45]  M. Israel,et al.  Cytogenetic characterization of selected small round cell tumors of childhood. , 1986, Cancer genetics and cytogenetics.

[46]  D. Dexter,et al.  Human tumor cell heterogeneity and metastasis. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J E Talmadge,et al.  Evidence for the clonal origin of spontaneous metastases. , 1982, Science.

[48]  K. Walsh,et al.  TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. , 1998, Nature medicine.

[49]  P. J. Middelhoven,et al.  Involvement of a metalloprotease in the shedding of human neutrophil Fc gammaRIIIB. , 1997, FEBS letters.

[50]  L. Weiss,et al.  Metastatic inefficiency. , 1990, Advances in cancer research.

[51]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[52]  T. Triche,et al.  Olfactory neuroblastoma is not a neuroblastoma but is related to primitive neuroectodermal tumor (PNET). , 1988, Progress in clinical and biological research.